CCL18 and breast cancer: In addition, CCL18-producing TAMs also promoted in vitro human umbilical vein endothelial cell (HUVEC) migration and tube formation, tumor angiogenesis, and EMT of breast cancer cells via its receptor PITPNM3 [154].